Sort by
Refine Your Search
-
immunosuppression, akin to PDL1-PD1 interactions. In collaboration with Carolyn Bertozzi’s group, we are developing bifunctional proteins that include an antibody to cell surface cancer proteins (e.g. PSMA, CA9) and
-
-genomically templated CD8+ T cell epitopes derived from the proteasome catalyzed splicing of peptides (PCPS). Our work suggests that PCPS peptides are dependent on protein structure and not just the mutated
-
the mechanism of membrane protein biogenesis and quality control at the human endoplasmic reticulum using a combination of cutting-edge functional genomics, cell biology, structural biochemistry and
-
tumor spatial biology via single cell spatial analysis of the tumor microenvironment. Projects aim to reveal molecular mechanisms of drug resistance based on intercellular and intracellular regulation
-
. The project provides a unique opportunity to use clinically relevant animal models, transgenic mice, in vitro and ex vivo cultures, live cell and tissue imaging, single cell technologies, and bioinformatic
-
Position in Stem Cell Neuroscience and Spinal Cord Injury and Repair. Dr. Irene L. Llorente, Assistant Professor in the Neurosurgery Department, is recruiting a full-time postdoctoral fellow for a CIRM
-
-new lab that previously made important contributions to the development of novel predictive computational tools in single cell and spatial transcriptomics. Representative publications include
-
(Siglecs) on immune cells to effect immunosuppression, akin to PDL1-PD1 interactions. In collaboration with Carolyn Bertozzi’s group, we are developing bifunctional proteins that include an antibody to cell
-
following hematopoietic stem cell transplantation. Our group works on developing targeted tools which abrogate impairments in mitochondrial dynamics as therapeutic candidates for the treatment
-
., Cancer Discovery, 2024; Luca, Steen et al., 2021, Cell), efforts to reveal biomarkers of in situ breast cancer progression (Strand et al., Cancer Cell, 2022; Risom et al. Cell, 2022), and response to PD-1